Furthermore, in a clinical trial of IL-1 inhibitors that primarily investigated the effect of an IL-1β inhibitor for lowering the risk of hypertension and major adverse cardiovascular events, significant benefits for preventing adverse cardiovascular events were observed in a subgroup of patients with mild CKD34. Here, IL1B is linked to hypertensive disorder.